Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice

Abstract Background Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. “Smac mimetics” (also known as “IAP antagonists”) are a new class of anti-cancer agents. Previous work revealed that cells from murine osteosarcomas we...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Tanmay M. Shekhar, Ingrid J. G. Burvenich, Michael A. Harris, Angela Rigopoulos, Damien Zanker, Alex Spurling, Belinda S. Parker, Carl R. Walkley, Andrew M. Scott, Christine J. Hawkins
Format: Artigo
Jezik:Inglês
Izdano: BMC 2019-09-01
Serija:BMC Cancer
Teme:
Osteosarcoma
Bone cancer
Sarcoma
Smac mimetic
IAP antagonist
Metastasis
Online pristup:http://link.springer.com/article/10.1186/s12885-019-6103-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items